Janux Therapeutics, Inc. (JANX) Investor Relations Documents
Janux Therapeutics, Inc. (JANX) investor relations documents from the company's IR site: 3 presentations, 15 press releases; latest deck 2025-12-01. Read in-app with summaries. First-party data.
Download PDF file, (opens in new window): Janux Therapeutics reports Phase 1 clinical update for JANX007, a tumor-activated T-cell engager for prostate cancer, showing durable responses and manageable safety.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-06 | Press release | Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights |
| 2026-05-07 | Press release | Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights |
| 2026-01-26 | Press release | Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer |
| 2025-12-01 | Press release | Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC |
| 2025-12-01 | Presentation | Download PDF file, (opens in new window) |
| 2025-11-06 | Press release | Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights |
| 2025-07-24 | Presentation | Presentation Open Event Link, PDF file, July 24, 2025, (opens in new window) |
| 2024-12-02 | Presentation | Download PDF (opens in new window) |
| Press release | Press Release |
| Press release | Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 |
| Press release | Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 |
| Press release | Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development |
| Press release | Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 M |
| Press release | Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develo |
| Press release | Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study |
| Press release | Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC |
| Press release | Press Release of Q3 2023, aspx file, (opens in new window) |
| Press release | Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights |
JANX overview · JANX earnings · JANX financials · JANX KPIs · JANX documents · JANX ownership · JANX peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.